GlassScriptPhysician profile
Abel Mendez
NPI 1366896888
$2,327.71
in general payments reported to CMS, 2019-2025
23 companies · $552 in 2025
The $552 reported for 2025 was more than what 76% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $246 · 2022: $693 · 2023: $259 · 2024: $578 · 2025: $552.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,363 · Education: $26.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,362.61 |
| Education | $26.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $378.91 | 2024-2025 | Nuzyra |
| Viiv Healthcare Company | $281.65 | 2021-2025 | Cabenuva, Rukobia, Apretude |
| Grifols USA, LLC | $194.47 | 2022-2025 | Gamunex-C |
| Gilead Sciences, INC. | $184.78 | 2022-2025 | |
| Theratechnologies INC. | $160.37 | 2021-2024 | Egrifta, Trogarzo |
| Octapharma USA, INC. | $145.00 | 2022-2025 | Panzyga |
| Shionogi INC | $135.40 | 2021-2025 | Fetroja |
| Karyopharm Therapeutics INC. | $124.99 | 2024 | Xpovio |
| Csl Behring | $119.21 | 2021-2023 | Hizentra |
| Aimmune Therapeutics, INC. | $118.59 | 2024-2025 | Vowst |
| Abbvie INC. | $111.44 | 2022 | |
| Napo Pharmaceuticals INC | $57.07 | 2021-2022 | |
| Janssen Biotech, INC. | $40.02 | 2023 | Symtuza |
| Insmed, INC. | $39.23 | 2022 | |
| Merck Sharp & Dohme LLC | $33.93 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adma Biomanufacturing LLC | $31.39 | 2022 | |
| Redhill Biopharma INC. | $31.34 | 2023 | Talicia |
| Pharming Healthcare, INC. | $26.00 | 2024 | |
| Ferring Pharmaceuticals INC. | $25.50 | 2022 | |
| Genentech USA, INC. | $24.99 | 2021 | |
| Melinta Therapeutics, LLC | $22.17 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.81 | 2023 | Cuvitru |
| Mayne Pharma Commercial LLC | $20.45 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abel Mendez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.